Risk-Enhancing Factors for Lipid Disorders
Read More
Unmet Needs and Emerging Treatments for Psoriasis
Challenges in Treating Patients With Plaque Psoriasis
Elderly Male With Plaque Psoriasis, Metabolic Syndrome
49-Year-Old Female With Psoriasis and Latent Tuberculosis
Case Study of a 23-Year-Old Female With Plaque Psoriasis
IL-23 Inhibitors for Treatment of Plaque Psoriasis
Managing Depression as a Psychological Effect of Psoriasis
HIV as a Contraindication for Treatment of Psoriasis
Contraindications to the Conventional Treatment for Psoriasis
Adverse Events of TNF Inhibitors Used to Treat Psoriasis
Experience With Using Older Biologics to Treat Psoriasis
Medical Benefit of Office Administration of Tildrakizumab
Effect of Multiple Sclerosis and Obesity on Treatment of Psoriasis
Factors That Influence Choice of Treatment for Plaque Psoriasis
Clinical Manifestations and Progressive Nature of Psoriasis
Pathogenesis of Plaque Psoriasis and Triggering Factors
Summary
Case Study 3: Non-Radiographic Axial Spondylia Patient Case Overview and Therapeutic Goals
Case Study 2: Rheumatoid Arthritis Patient Case Overview and Therapeutic Goals
Case Study 1: Psoriatic Arthritis Patient Case Overview and Therapeutic Goals
Optimal Management of Hypercholesterolemia
ACS: Early Intervention With PCSK9 Therapy
Increasing Confidence in Prescribing PCSK9 Inhibitors
Real-World Experience With PCSK9 Inhibitors
Lipoprotein(a) and PCSK9 Utilization
Cardiovascular Outcomes: FOURIER and ODYSSEY
PCSK9 Inhibitors and LDL-C Reduction
Managing Intolerance to Statin Therapy
Selecting a Statin Therapy to Manage LDL-C